Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Overcoming the issues with clinical trial recruitment

Arnold Ganser • 4 May 2018
ESH AL 2018
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Midostaurin
RATIFY

Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, discusses the importance of collaborating with other trial groups that are focusing on acute leukemias by joining efforts with other experts at various networking events and conferences. Recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

More from Arnold Ganser

1:41
Finding the right targets for CAR T-cell therapy in AML
Arnold Ganser • 4 May 2018
2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser • 4 May 2018
3:00
The devastating effects of relapsed or refractory AML
Arnold Ganser • 4 May 2018
3:15
From bench to the bedside: understanding the genetic changes in AML
Arnold Ganser • 4 May 2018

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals